1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key Benefits for the Stakeholder
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Processes
3. EXECUTIVE SUMMARY
3.1. Key Findings
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View
5. VIRAL VECTOR MANUFACTURING MARKET BY TYPE
5.1. Introduction
5.2. Retroviral Vectors
5.3. Lentiviral Vectors
5.4. Adenoviral Vectors
5.5. Others
6. VIRAL VECTOR MANUFACTURING MARKET BY APPLICATION
6.1. Introduction
6.2. Vaccinology
6.3. Gene Therapy
7. VIRAL VECTOR MANUFACTURING MARKET BY END-USER
7.1. Introduction
7.2. Pharmaceutical & Biotechnology Companies
7.3. Research Institutes
7.4. Contract Research Organizations
8. VIRAL VECTOR MANUFACTURING MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. United States
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. United Kingdom
8.4.2. Germany
8.4.3. France
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. UAE
8.5.2. Saudi Arabia
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Thailand
8.6.6. Indonesia
8.6.7. Taiwan
8.6.8. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Sirion-Biotech GmbH
10.2. Vigene Biosciences
10.3. Batavia Biosciences B.V.
10.4. Virovek
10.5. Lonza
10.6. Vector Biolabs
10.7. Cobra Biologics
10.8. MaxCyte, Inc.
10.9. Genelux
10.10. BioNTech SE